Patent · US Active

Thrombin cleavable factor X analogues

US8168753B2 · kind B2 · utility

0Cited by

2References

8Claims

0Family size

Assignee

Institut National de la Sante et de la Recherche Medicale (INSERM) · FR

Inventors

Virginie Louvain · Verrières-le-Buisson, FR
Elsa Bianchini · Philadelphia, US
Pierre-Emmanuel Marque · Paris, FR
Claire Calmel-Tareau · Paris, FR
Martine Aiach · Sèvres, FR
Bernard Le Bonniec · Paris, FR

Key dates

Filing date	Jun 30, 2003
Grant date	May 1, 2012
Priority date	—
Expiry date	Jul 2, 2026

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K38/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to factor X analogues containing the thrombin-cleavable sequence Pro-Arg-Ala in place of the-sequence Thr-Arg-Ile of the activation site of native factor X. These factor X analogues can be used to obtain procoagulant medicinal products.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.